Pharming presents at the first "PharmingForum" Day on the 26th of October 2019 in Gilze en Rijen. Pharming was honoured to present to the forum members alongside our esteemed colleague Professor Michael Osthoff, M.D. from Basel University.
CSL Behring and Pharming have mutually agreed that CSL will dismiss Pharming from the case against Dr. Chiao.
Pharming categorically denies having had any involvement in the alleged abstraction of proprietary information by Dr Joseph Chiao from his former employer CSL
CEO of Pharming Sijmen de Vries presented at the 21st Annual Global Life Science Investment Conference on the 9th of September in New York City.
Pharming Group N.V. announces it has entered into a development collaboration and license agreement with Novartis to develop and commercialize CDZ173, a small molecule phosphoinositide 3-kinase delta (PI3Kẟ) inhibitor being developed by Novartis to treat patients with Activated Phosphoinositide 3-kinase Delta Syndrome (“APDS”).
Pharming Group reports strong financial results for the first half of 2019.
Pharming Webinar: halfjaarcijfers 2019 donderdag 25 juli 2019 tussen 19.00 en 20.00 uur. Nu aanmelden!
Following receipt of the Dutch investigating centre’s ethics committee approval, Pharming announces it is commencing a clinical study of the effects of its recombinant human C1 esterase inhibitor (rhC1INH), RUCONEST®, in patients with pre-eclampsia.
Pharming announces that at its Annual General Meeting of shareholders (AGM), held today, all proposals were approved. The presentation slides from today’s AGM are available on the Company’s website.
